Interpreting immunogenicity in oncology clinical trials

By afschroeder • September 1, 2025

Galle PR, Reck M, Pinato DJ, Garcia-Campelo R, Finn RS, Cousin S, Zanghi J, Bernaards CA, Swanson SJ, Morris S, Song Y, Peters S. Interpreting immunogenicity in oncology clinical trials. Cancer Treat Rev. 2025 Aug 25;140:103016. doi: 10.1016/j.ctrv.2025.103016. Epub ahead of print. PMID: 40886486.

Tags: Hematology/Oncology, Publications

Related Posts

Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer

Rodon J, O'Neil B, Lim C, Ammakkanavar NR, Torrado C, Matsuoka K, Hirai H, Miura A, Anderson B, Jin L, Hangai N, Long A, Wacheck[...]

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma

Galsky MD, Drakaki A, Basu A, McGregor B, Bedke J, Loriot Y, Kikuchi E, Guo J, Garmezy B, Sridhar SS, Singh P, Koshkin VS, Fleming[...]

Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer

Swisher EM, Konecny G, Cohen J, Colon-Otero G, Danziger N, Lin DI, Li G, Quintanilha JCF, Decker B, Ross JS, Gearing M, Baker K, Scott[...]